TP53 and endometrial cancer: ENDORISK, a validated risk algorithm based on four pre-operative molecular markers, namely L1CAM, PR, ER, and p53 status, predicted risk of lymph node metastasis and survival in a multi-centric cohort of 763 women with endometrial cancer across Europe, and 2 independent cohorts from the Netherlands and Norway (64).